Corporate Information – Page 17

Grant of options

21.11.2017

Faron Pharmaceuticals Ltd

(“Faron” or the “Company”)

Grant of options

TURKU – FINLAND, 21 November 2017 – Faron (LON: FARN), the clinical stage biopharmaceutical company, announces that on 16 November 2017 the Board of Faron confirmed the subscription for a total of 500,000 C options over ordinary shares in the Company (“Options”) under the Faron 2015 Option Plan. The Options have been allocated under the Faron 2015 Option Plan and are exercisable between 8 October 2017 and 30 September 2021 at an exercise price of 839 euro cents per share. The exercise price is calculated based on the average share price between 1 July and 30 September 2017. The details of the 2015 Option Plan, as amended, are described in the 2017 annual general meeting material, which is available on Company’s website.

The granted 500,000 Options entitle the option holders to subscribe for a total of 500,000 new ordinary shares in the Company, if exercised in full, and represent 1.68% of the fully-diluted Ordinary Share Capital of the Company.

Included in the number of Options in respect of which the Board of Faron has confirmed subscriptions are the following Options which were issued to Directors and other Persons Discharging Managerial Responsibility (“PDMRs”):

Director	Options granted
Markku Jalkanen	80,000
Frank Armstrong	40,000
Yrjö E K Wichmann	30,000
Matti Manner	20,000
Jonathan Knowles	20,000
Huaizheng Peng	20,000
Leopoldo Zambeletti	20,000
Gregory Brown	20,000
John Poulos	20,000
Total Directors	270,000
PDMRs
Mikael Maksimow	32,270
Matti Karvonen	32,270
Jami Mandelin	32,270
Juho Jalkanen	32,270
Total PDMRs	129,080

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nominated Adviser and Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials and in 2017 received advice from US FDA to proceed directly to BLA submission following completion of EU and Japanese Phase III studies. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Markku Jalkanen

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

80,000

Aggregated information

– Aggregated Volume

– Price

80,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Frank Armstrong

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

40,000

Aggregated information

– Aggregated Volume

– Price

40,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Yrjö E K Wichmann

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

30,000

Aggregated information

– Aggregated Volume

– Price

30,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Matti Manner

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

20,000

Aggregated information

– Aggregated Volume

– Price

20,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Jonathan Knowles

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

20,000

Aggregated information

– Aggregated Volume

– Price

20,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Huaizheng Peng

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

20,000

Aggregated information

– Aggregated Volume

– Price

20,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Leopoldo Zambeletti

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

20,000

Aggregated information

– Aggregated Volume

– Price

20,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Gregory Brown

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

20,000

Aggregated information

– Aggregated Volume

– Price

20,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

John Poulos

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

20,000

Aggregated information

– Aggregated Volume

– Price

20,000

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Mikael Maksimow

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

32,270

Aggregated information

– Aggregated Volume

– Price

32,270

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Matti Korvonen

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

32,270

Aggregated information

– Aggregated Volume

– Price

32,270

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Jami Mandelin

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

32,270

Aggregated information

– Aggregated Volume

– Price

32,270

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Juho Jalkanen

Reason for notification

Position/Status

Person discharging managerial responsibilities

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Options over ordinary shares

ISIN: FI4000153309

Nature of the transaction

Grant of options made pursuant to the Faron 2015 Option Plan exercisable at 839 Euro cents per Ordinary Share

Price(s) and volume(s)

Price(s)

Volume(s)

Nil

32,270

Aggregated information

– Aggregated Volume

– Price

32,270

Nil

Date of the transaction

16 November 2017

Place of the transaction

Turku

Change of Adviser

20.11.2017

RNS Number : 8781W

Faron Pharmaceuticals Oy

20 November 2017

Faron Pharmaceuticals Ltd
(“Faron” or the “Company”)

Change of Adviser

TURKU – FINLAND, 20 November 2017 – Faro (LON: FARN), the clinical stage biopharmaceutical company, announces the appointment of Panmure Gordon (UK) Limited as the Company’s Nominated Adviser, in addition to its existing appointment as Broker, with immediate effect.

–ENDS–

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nominated Adviser and Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPFFMFIWFWSEEF

Holding(s) in Company

16.10.2017

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ: New issue						X
3. Details of person subject to the notification obligation^iv
Name			City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund
City and country of registered office (if applicable)			London, United Kingdom
4. Full name of shareholder(s) (if different from 3.)^v
Name			BNY Mellon Trust and Depositary as Trustee to the City Financial Absolute Equity Fund
City and country of registered office (if applicable)			London, United Kingdom
5. Date on which the threshold was crossed or reached^vi:			11/10/2017
6. Date on which issuer notified (DD/MM/YYYY):			13/10/2017
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached	4.02%	0		4.02%	1,172,530
Position of previous notification (if applicable)	3.98%	N/A		3.98%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
FI4000153309		1,172,530		0			4.02%		0


SUBTOTAL 8. A		1,172,530					4.02%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold






10. In case of proxy voting, please identify:
Name of the proxy holder		NA
The number and % of voting rights held		NA
The date until which the voting rights will be held		NA

11. Additional information^xvi

Place of completion	City Financial Investment Company Limited, London
Date of completion	13/10/2017

Director/PDMR Shareholding

13.10.2017

RNS Number : 5371T

Faron Pharmaceuticals Oy

13 October 2017

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (“PDMR”)

The notification below is being made in accordance with the requirements of the EU Market Abuse Regulation with reference to Dr Frank Armstrong’s participation in the Placing and Subscription announced by the Company on 11 October 2017.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Frank Armstrong

Reason for notification

Position/Status

Person discharging managerial responsibilities

Non-executive Chairman

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309

Nature of the transaction

Subscription

Price(s) and volume(s)

Price(s)

Volume(s)

800 GBPp

1,250

Aggregated information

– Aggregated Volume

– Price

1,250

10,000 GBP

Date of the transaction

11 October 2017

Place of the transaction

Off-exchange transaction

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHOKNDQOBDKFKD

Directors Dealings

11.9.2017

RNS Number : 4113Q

Faron Pharmaceuticals Oy

11 September 2017

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

Director’s Dealing

TURKU – FINLAND, 11 September 2017 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 11 September 2017 it was notified that on 8 September 2017 Dr Jonathan Knowles, a Non-Executive Director of the Company, acquired 63,000 ordinary shares in Faron at a price of 725 pence per ordinary share. Following the purchase, Dr Knowles holds 110,712 ordinary shares in the Company.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Jonathan Knowles

Reason for notification

Position/Status

Person discharging managerial responsibilities

Director

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309

Nature of the transaction

Purchase of Ordinary Shares

Price(s) and volume(s)

Price(s)

Volume(s)

725 GBPp

63,000

Aggregated information

– Aggregated Volume

– Price

63,000

456,750.00 GBP

Date of the transaction

8 September 2017

Place of the transaction

Basle

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFLSARILLID

Holding(s) in Company

28.7.2017

RNS Number : 4177M

Faron Pharmaceuticals Oy

28 July 2017

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ


1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Faron Pharmaceuticals Oy
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.):^iv	Registered Holder: Chase (GA Group) Nominees Limited 1,151,067* HSBC Global Custody Nominee (UK) Limited 302,062* State Street Nominees Limited 35,452* * denotes direct interest Chase (GA Group) Nominees Limited 57,059 Chase Nominees Limited 35,158
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	26 July 2017
6. Date on which issuer notified:	27 July 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	6% to 5% Change at Combined Interest Level. Figures are provided in accordance with provisions of your company articles and not in fulfilment of the requirements of the Transparency Directive.

8. Notified details:
A: Voting rights attached to shares ^{viii, ix}
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights			% of voting rights ^x
					Direct	Direct ^xi		Indirect ^xii	Direct		Indirect
Ordinary Shares FI4000153309	1,910,798		1,910,798		1,580,798	1,488,581		92,217	5.33%		0.33%


B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date ^xiii		Exercise/ Conversion Period ^xiv			Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date ^xvii	Exercise/ Conversion period ^xviii	Number of voting rights instrument refers to	% of voting rights ^{xix, xx}
					Nominal	Delta

Total (A+B+C)
Number of voting rights				Percentage of voting rights
1,580,798				5.66%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Proxy Voting:
10. Name of the proxy holder:	See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:	Figures are based on a total number of voting rights of 27,914,544 as per the company’s Announcement of 1 June 2017.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	00 44 1603 684420

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLFMGZNRRGGNZG

Holding(s) in Company

10.7.2017

RNS Number : 6404K

Faron Pharmaceuticals Oy

10 July 2017

For filings with the FCA include the annex
For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Faron Pharmaceuticals Oy
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.):^iv	Registered Holder: Chase (GA Group) Nominees Limited 1,414,752* HSBC Global Custody Nominee (UK) Limited 347,410* State Street Nominees Limited 35,452* * denotes direct interest Chase (GA Group) Nominees Limited 71,497 Chase Nominees Limited 41,687
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	05 July 2017
6. Date on which issuer notified:	07 July 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	7% to 6% Change at Combined Interest Level. Figures are provided in accordance with provisions of your company articles and not in fulfilment of the requirements of the Transparency Directive.

8. Notified details:
A: Voting rights attached to shares ^{viii, ix}
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction				Resulting situation after the triggering transaction
	Number of Shares		Number of Voting Rights		Number of shares	Number of voting rights			% of voting rights ^x
					Direct	Direct ^xi		Indirect ^xii	Direct		Indirect
Ordinary Shares FI4000153309	1,910,798		1,910,798		1,797,614	1,797,614		113,184	6.44%		0.41%


B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument		Expiration date ^xiii		Exercise/ Conversion Period ^xiv			Number of voting rights that may be acquired if the instrument is exercised/ converted.			% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}
Resulting situation after the triggering transaction
Type of financial instrument	Exercise price	Expiration date ^xvii	Exercise/ Conversion period ^xviii	Number of voting rights instrument refers to	% of voting rights ^{xix, xx}
					Nominal	Delta

Total (A+B+C)
Number of voting rights				Percentage of voting rights
1,910,798				6.85%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chains of controlled undertakings:- Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Proxy Voting:
10. Name of the proxy holder:	See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:	Figures are based on a total number of voting rights of 27,914,544 as per the company’s Announcement of 1 June 2017.
14. Contact name:	Neil Whittaker, Aviva plc
15. Contact telephone number:	00 44 1603 684420

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLDMGMNKGVGNZM

Notice of Results

10.7.2017

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

Notice of Interim Results

TURKU – FINLAND, 10 July 2017 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, will be announcing its interim results for the six months ended 30^th June, 2017 on Wednesday 6^th September, 2017.

Dr Markku Jalkanen, Chief Executive Officer and Yrjö Wichmann, Chief Financial Officer, will host a presentation and conference call for analysts at 9:30am BST on the day of the results at the offices of Panmure Gordon & Co, 1 New Change, London, EC4M 9AF.

– END –

For more information, please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faronpharmaceuticals.com

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, cancer immunotherapy and vascular damage. The pipeline is built on Faron’s scientific knowledge and control of the endothelial barrier, the membrane of cells lining blood and lymphatic vessels to separate blood content from tissues. The Company’s lead candidate Traumakine® is in development for the treatment of Acute Respiratory Distress Syndrome (“ARDS”), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine is currently in pan-European (INTEREST) and Japanese pivotal Phase III studies. Additionally, Faron is developing Clevegen® a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to convert the immune environment around a tumour from being immune suppressive to immune stimulating. This novel macrophage-directed immuno-oncology approach is called Tumour Immunity Enabling Technology (“TIET”) and can be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. New application opportunities related to TIET cover chronic infections and inefficient vaccination. Based in Turku, Finland, Faron Pharmaceuticals is listed on AIM under the ticker ‘FARN’. Further information is available at www.faronpharmaceuticals.com

Director/PDMR Shareholding

16.6.2017

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

Director/PDMR Shareholding

Shares used for collateral of a personal bank loan of the Director

TURKU – FINLAND, 16 June 2017 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 13 June 2017 Dr Juho Jalkanen, Vice President of Business Development of Faron, pledged 70,000 ordinary shares of the Company (“Ordinary Shares”) held by him, as collateral for a personal bank loan provided to Dr Jalkanen (“Collateral Shares”). Dr Jalkanen’s total holding in the Company, including that of his family, continues to be 1,082,570 ordinary shares (including the Collateral Shares). The total number of Ordinary Shares held by Dr Jalkanen and pledged as collateral is 125,000 Ordinary Shares.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

Details of the person discharging managerial responsibilities/person closely associated

Name

Juho Jalkanen

Reason for notification

Position/Status

Person discharging managerial responsibilities

Vice President of Business Development of Faron

Initial notification/

Amendment

Initial Notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

Faron Pharmaceuticals Oy

LEI

7437009H31TO1DC0EB42

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309

Nature of the transaction

Shares used for collateral of a personal bank loan of the Director

Price(s) and volume(s)

Price(s)

Volume(s)

735 pence

70,000

Aggregated information

– Aggregated Volume

– Price

70,000

GBP514,500.00

Date of the transaction

13 June 2017

Place of the transaction

Turku

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: +44 207 213 0880

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen® is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faronpharmaceuticals.com

Holdings in Company

30.5.2017

RNS Number : 5889G

Faron Pharmaceuticals Oy

30 May 2017


TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Faron Pharmaceuticals Oy
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	City Financial Investment Company Limited, acting as Investment Manager and Authorised Corporate Director of the City Financial Absolute Equity Fund
4. Full name of shareholder(s) (if different from 3.):^iv	BNY Mellon Trust and Depositary as Trustee to the City Financial Absolute Equity Fund
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	26 May 2017
6. Date on which issuer notified:	30 May 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	4%

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

1,105,530

1,140,530

1,105,530

3.98%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,105,530

3.98%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
The voting rights are managed and controlled by City Financial Investment Company Limited, Investment manager and ACD to the City Financial Absolute Equity Fund.

Proxy Voting:
10. Name of the proxy holder:
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:
14. Contact name:	Ben Ellenbogen
15. Contact telephone number:	0207 451 9600

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLXBLFXDEFBBBZ